Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

The first-line screening test, which detects the HBV surface antigen, is affordable and accessible in many low-income countries. But the second test, which uses PCR to measure viral load ...

Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA ...

They are considered protected if they have a hepatitis B surface antigen antibody (anti-HBs) titer of ≥10 mIU/mL after completing a full vaccination series. This study compared the effectiveness ...

Large-scale data on the hepatitis D virus (HDV)/hepatitis B virus (HBV) co-infection rate is needed to estimate the current epidemiology of HDV in China. This study aimed to estimate the current ...

AMALAPURAM: Health authorities in Konaseema district have reported a spike in hepatitis infections in Pallam village, following over 10 days of persistent fever ...

Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and ...

A team of Northwestern University scientists spanning disciplines have developed new technology that could lead to the creation of a rapid point-of-care test for HIV infection competitive with ...

They are considered protected if they have a hepatitis B surface antigen antibody (anti-HBs) titer of ≥10 mIU/mL after completing a full vaccination series. This study compared the effectiveness ...

A team of Northwestern University scientists spanning disciplines have developed new technology that could lead to the creation of a rapid point-of-care test for HIV infection competitive with ...

Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...